About Us
Our Company
Management & Board
Who We Help
Our Approach
Toll-Like Receptor Activation
Publications & Presentations
Areas of Focus
Immuno-Oncology
Pipeline & Programs
Investor Relations
Join Us
×
Design of a randomized, double-blind, placebo-controlled Phase 2 clinical trial of IMO-8400, a Toll-like receptor antagonist, in patients with dermatomyositis